ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials.
Ratings
0 / 5
0 ratings in the last 12 months
5
4
3
2
1
CEO
Mr. Jason Lettmann$789.4M
Market Cap • 18/04/20242020
(há 4 anos)
2020
(4 years ago)
NASDAQ
Listagem
South San Francisco
Sede • California58
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
ALXOSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.